Holen Sie sich die Stockscreener-App
0.00
100.00%
-1.74
Schlusskurs vom Vortag:
$1.74
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$45.77M
Einnahmen:
$4.99M
Nettoeinkommen (Verlust:
$-28.29M
KGV:
0.00
EPS:
-1.0528
Netto-Cashflow:
$-36.20M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$1.825
Lava Therapeutics Nv Stock (LVTX) Company Profile
Firmenname
Lava Therapeutics Nv
Sektor
Branche
Telefon
31 6 3000 3035
Adresse
YALELAAN 62, UTRECHT
Compare LVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
0.00 | 45.77M | 4.99M | -28.29M | -36.20M | -1.0528 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.81 | 119.38B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.63 | 81.46B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
820.31 | 52.65B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 46.50B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.00 | 38.95B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-04-19 | Eingeleitet | Jefferies | Buy |
| 2021-04-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lava Therapeutics Nv Aktie (LVTX) Neueste Nachrichten
Investor Mood: Is LAVA Therapeutics NV benefiting from innovation trendsIPO Watch & Growth Focused Entry Reports - baoquankhu1.vn
LAVA Therapeutics Approves Merger with New Topco B.V. - MSN
Risk Off: Does LAVA Therapeutics NV stock benefit from AI growth2025 Geopolitical Influence & AI Based Trade Execution Alerts - baoquankhu1.vn
Market Rankings: What is the Moat Score of LAVA Therapeutics NVJuly 2025 Pullbacks & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Is LAVA Therapeutics N.V. stock a buy before product launchesBlue Chip Stock Analysis & Minimal Capital Trading Plans - Bollywood Helpline
Will LAVA Therapeutics N.V. stock reach all time highs in 2025July 2025 Highlights & Reliable Volume Spike Alerts - Bollywood Helpline
Market Recap: Is LAVA Therapeutics NV forming a double bottomStock Surge & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Moving Averages: How LAVA Therapeutics NV stock reacts to inflationary pressuresBreakout Watch & Daily Profit Focused Stock Screening - Bộ Nội Vụ
Biotech royalty firm XOMA shifts finance leadership after nearly 20 years - Stock Titan
Is LAVA Therapeutics N.V. stock recession proofWeekly Gains Summary & Consistent Profit Trade Alerts - Улправда
Can LAVA Therapeutics N.V. stock hit record highs againJuly 2025 Institutional & Low Risk High Win Rate Stock Picks - Улправда
XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics - MSN
What analysts say about LAVA Therapeutics NV 4PKB stockEarnings Forecast Updates & Free Dynamic Capital Growth - earlytimes.in
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
HC Wainwright & Co. Downgrades LAVA Therapeutics N.V. (LVTX) - MSN
Will LAVA Therapeutics N.V. stock see insider buyingJuly 2025 Patterns & High Conviction Investment Ideas - Улправда
Published on: 2025-12-20 11:31:17 - Улправда
Is LAVA Therapeutics N.V. (4PKB) stock worth buying before Fed actionMarket Sentiment Report & Comprehensive Market Scan Reports - DonanımHaber
How dovish Fed policy supports LAVA Therapeutics N.V. (4PKB) stockOptions Play & Weekly Watchlist for Hot Stocks - DonanımHaber
How LAVA Therapeutics N.V. stock reacts to job market data2025 Sector Review & AI Enhanced Trading Alerts - Улправда
Is LAVA Therapeutics N.V. (4PKB) stock dividend growth reliableMarket Volume Summary & Momentum Based Trading Ideas - Улправда
Published on: 2025-12-18 13:21:42 - Улправда
Volume Recap: Is LAVA Therapeutics NV 4PKB stock worth buying before Fed actionAnalyst Downgrade & Short-Term Trading Opportunity Alerts - moha.gov.vn
LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Consensus Recommendation of “Reduce” by Analysts - Defense World
Xoma Royalty Expands Portfolio Through Mural Oncology Acquisition - AD HOC NEWS
XOMA Royalty (Nasdaq: XOMA) completes $2.035 per share Mural Oncology takeover - stocktitan.net
Total debt per share of LAVA Therapeutics NV – BER:4PKB - TradingView
Operating cash flow per share of LAVA Therapeutics NV – SWB:4PKB - TradingView
Can LAVA Therapeutics N.V. (4PKB) stock expand revenue streamsMarket Activity Recap & Daily Volume Surge Signals - Newser
Why LAVA Therapeutics N.V. (4PKB) stock is listed among top recommendations2025 Growth vs Value & Daily Stock Trend Reports - Newser
Is LAVA Therapeutics NV overvalued or undervalued? - Markets Mojo
LAVA Therapeutics (LVTX) Expected to Announce Earnings on Tuesday - Defense World
LAVA Therapeutics NV Financial Disclosures & Filings - TradingView
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - ADVFN
XOMA Royalty completes acquisition of LAVA Therapeutics By Investing.com - Investing.com Nigeria
Lava Therapeutics shares delisted from Nasdaq following completion of acquisition - Investing.com Nigeria
Lava Therapeutics shares delisted from Nasdaq following completion of acquisition By Investing.com - Investing.com South Africa
XOMA Completes Acquisition of LAVA Therapeutics - TipRanks
[SC TO-T/A] LAVA Therapeutics NV Amended Third-Party Tender Offer | LVTX SEC FilingForm SC TO-T/A - Stock Titan
XOMA Royalty completes acquisition of LAVA Therapeutics - Investing.com
LAVA Therapeutics Announces Executive Departures - TradingView
[8-K] LAVA Therapeutics NV Reports Material Event | LVTX SEC FilingForm 8-K - Stock Titan
Xoma Royalty announces closing of transactions to acquire LAVA Therapeutics N.V. - MarketScreener
XOMA Royalty Corporation Completes Acquisition of LAVA Therapeutics N.V. - Quiver Quantitative
XOMA Royalty (Nasdaq: XOMA) completes LAVA deal; investors get $1.04 plus CVR - Stock Titan
Will LAVA Therapeutics N.V. stock benefit from AI adoption2025 Big Picture & Weekly High Return Opportunities - newser.com
What makes LAVA Therapeutics N.V. (4PKB) stock appealing to growth investorsIPO Watch & High Return Stock Watch Alerts - newser.com
EBIT per share of LAVA Therapeutics NV – MUN:4PKB - TradingView
Finanzdaten der Lava Therapeutics Nv-Aktie (LVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
2.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):